Literature DB >> 1691908

Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.

M F Prummel1, W M Wiersinga, M P Mourits, L Koornneef, A Berghout, R van der Gaag.   

Abstract

Many clinicians have the impression that treatment of thyroid dysfunction ameliorates ophthalmopathy in Graves' disease. The aim of our study was to relate thyroid function to the severity of Graves' ophthalmopathy. We studied 90 patients with Graves' ophthalmopathy and Graves' hyperthyroidism in whom severity of Graves' ophthalmopathy and thyroid function (regardless of antithyroid treatment) were assessed when referred to our institution. Patients were assigned to four groups (A through D) with increasingly severe Graves' ophthalmopathy using Total Eye Score based on the NOSPECS classification. The percentage of dysthyroid patients in each group was determined: group A had 23% dysthyroid patient (5); group B, 32% (9); group C, 61% (14); and group D, 47% (8). More dysthyroid patients were in the groups with severe Graves' ophthalmopathy. We also compared the severity of Graves' ophthalmopathy between euthyroid (n = 54) and dysthyroid (n = 36) patients: euthyroid patients had less proptosis (19.9 +/- 3.5 vs 20.8 +/- 3.4 mm), better visual acuity (0.93 +/- 0.17 vs 0.88 +/- 0.18), and lower Total Eye Score (8.6 +/- 6.6 vs 10.6 +/- 6.6). We conclude that dysthyroidism is associated with more severe Graves' ophthalmopathy. Our findings suggest that meticulous control of thyroid function also during antithyroid treatment is important in the management of Graves' ophthalmopathy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691908

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  40 in total

Review 1.  Relationship between cigarette smoking and Graves' ophthalmopathy.

Authors:  L Hegediüs; T H Brix; P Vestergaard
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

Review 2.  [Endocrine orbit disorders. Pathogenesis, clinical presentation and examination, stage-dependent therapy].

Authors:  A Eckstein; J Esser
Journal:  Ophthalmologe       Date:  2003-10       Impact factor: 1.059

3.  Thyroid-associated orbitopathy.

Authors:  Adel H Alsuhaibani; Jeffrey A Nerad
Journal:  Semin Plast Surg       Date:  2007-02       Impact factor: 2.314

Review 4.  Diagnosis and management of Graves disease: a global overview.

Authors:  Luigi Bartalena
Journal:  Nat Rev Endocrinol       Date:  2013-10-15       Impact factor: 43.330

Review 5.  Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy?

Authors:  C Marcocci; L Bartalena; A Pinchera
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

6.  Relationship between serum cholesterol and Graves' orbitopathy (GO): a confirmatory study.

Authors:  G Lanzolla; E Sabini; M A Profilo; B Mazzi; A Sframeli; R Rocchi; F Menconi; M Leo; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2018-06-19       Impact factor: 4.256

Review 7.  Prevalence and natural history of Graves' orbitopathy in the XXI century.

Authors:  E Piantanida; M L Tanda; A Lai; L Sassi; L Bartalena
Journal:  J Endocrinol Invest       Date:  2013-04-16       Impact factor: 4.256

8.  Update on the medical treatment of Graves' ophthalmopathy.

Authors:  Gregory J Griepentrog; James A Garrity
Journal:  Int J Gen Med       Date:  2009-12-29

9.  Risk factors associated with the severity of thyroid-associated orbitopathy in Korean patients.

Authors:  Ji Hwan Lee; Sang Yeul Lee; Jin Sook Yoon
Journal:  Korean J Ophthalmol       Date:  2010-10-05

10.  Update on thyroid eye disease and management.

Authors:  Erick D Bothun; Ryan A Scheurer; Andrew R Harrison; Michael S Lee
Journal:  Clin Ophthalmol       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.